(TOVX) Theriva Biologics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TOVX) Theriva Biologics, Inc. Complete Analysis Pack
Theriva Biologics: Business Model Canvas Snapshot
Unlock the full strategic blueprint behind Theriva Biologics, Inc.’s business model. This concise Business Model Canvas highlights how the company creates value, manages key partnerships, and positions itself in a competitive biotech landscape. Ideal for investors, analysts, and strategists who want actionable insight—get the full version to see every building block in detail.
Partnerships
Intrexon platform collaboration
Theriva Biologics, Inc. relies on its Intrexon Corporation collaboration to support engineered biologic programs and its synthetic-biology drug design platform. This is a core external technology link for platform development, helping build assets such as oncolytic-virus programs without carrying all discovery work in-house.
University of Texas at Austin alliance
The University of Texas at Austin is listed as a collaborator, giving Theriva Biologics academic backing for translational research and early-stage validation. That support helps turn discovery work into testable clinical hypotheses, which can reduce scientific risk before costly development steps.
Cedars-Sinai Medical Center collaboration
Theriva Biologics, Inc. lists Cedars-Sinai Medical Center as a named partner, linking the company to a top-tier clinical and research hub with 900+ active research projects and 2,000+ physicians. That partnership adds trial design input, disease expertise, and faster access to real-world clinical insight for Theriva Biologics, Inc.
Washington University trial agreement
Theriva Biologics, Inc. has a clinical trial agreement with Washington University School of Medicine in St. Louis to run the Phase 1b/2a SYN-004 study. This partnership is core to execution because it supports site activity, protocol delivery, and patient enrollment for the trial.
- Phase 1b/2a SYN-004 trial support
- Direct link to enrollment and execution
- Academic partner: Washington University
Clinical investigators and study sites
Theriva Biologics, Inc. depends on specialist investigators and hospital sites to run oncology, transplant, and infectious-disease trials; about 80% of clinical trials face enrollment delays, so site access is a key execution risk and speed driver.
These partners screen patients, manage protocol compliance, and generate the clinical data needed for regulatory advancement.
- Recruit hard-to-find patients
- Run trial visits and data capture
- Support regulator-ready evidence
Theriva Biologics Leans on Top Partners to Advance Platform Science
Theriva Biologics, Inc. depends on partner labs and hospitals for platform science and clinical execution: Intrexon supports engineered-biologic work, while Washington University School of Medicine runs SYN-004 in Phase 1b/2a. Cedars-Sinai and the University of Texas at Austin add translational and academic validation.
| Partner | Role | Data |
|---|---|---|
| Washington University | Trial execution | Phase 1b/2a SYN-004 |
| Cedars-Sinai | Clinical insight | 900+ projects; 2,000+ physicians |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Theriva Biologics, mapping its oncology-focused pipeline, partners, and commercialization strategy.
Customizable Excel Spreadsheet
Quickly spot Theriva Biologics’ pain points and value drivers in a clear, one-page business snapshot.
Reference Sources
Provides a clear source trail for Theriva Biologics, Inc., helping users verify assumptions fast and make decisions with greater confidence.
Activities
Clinical-stage drug development
Theriva Biologics’ core activity is advancing its clinical-stage pipeline, moving assets from concept into human studies across microbiome, gastrointestinal, infection, and oncology programs. In fiscal 2025, this work remained the main R&D use of capital, so execution depends on timely study starts, patient enrollment, and clear clinical readouts.
Phase 1b/2a SYN-004 study
Theriva Biologics, Inc. is running the Phase 1b/2a SYN-004 study to test whether this oral beta-lactamase can degrade beta-lactam antibiotics in the GI tract without weakening systemic treatment. The work is aimed at building human safety and efficacy data for the program, which has advanced into early clinical testing.
Oncology asset advancement
Theriva Biologics is advancing 2 oncology assets, VCN-01 and VCN-11, through translational and clinical work for pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. This activity centers on trial design, biomarker work, and dose finding, where early-stage cancer programs often fail before proof of benefit.
Microbiome and GI platform work
Theriva Biologics is using one microbiome and GI platform to advance four programs: SYN-020, SYN-006, SYN-007, and SYN-005. The work targets intestinal health, infection prevention, and antibiotic-related complications, so one biological strategy supports multiple shots on goal.
- 4 linked assets
- One shared GI strategy
- Focus: gut health and infections
Regulatory and CMC execution
Theriva Biologics, Inc. must keep regulatory filings, quality systems, and manufacturing readiness in lockstep, because clinical biologics need tight chemistry, manufacturing, and controls (CMC) before late-stage trials or any launch. That work is the gatekeeper: if the process drifts, the product can miss specs, delay filings, or block scale-up.
- Manage FDA and global filings
- Prove batch consistency and quality
- Keep manufacturing launch-ready
Theriva’s 2025 Focus: Advancing GI and Oncology Programs
Theriva Biologics’ key activities in fiscal 2025 centered on advancing a 4-asset microbiome and GI platform plus 2 oncology programs through early clinical and translational work. The main job is still trial execution, biomarker work, and CMC readiness.
| Activity | 2025 focus | Data point |
|---|---|---|
| Pipeline | Early clinical execution | 4 GI assets, 2 oncology assets |
| Clinical work | SYN-004 Phase 1b/2a | Human safety and efficacy data |
Delivered as Displayed
Business Model Canvas
This Theriva Biologics, Inc. Business Model Canvas preview is taken directly from the final document you’ll receive after purchase. It is not a mockup or sample—what you see here is the same professionally formatted file, with the same structure and content. Once your order is complete, you’ll get instant access to this exact document, ready to edit, present, or share.
Resources
7 named pipeline assets
Theriva Biologics’ key resources are its 7 named pipeline assets: SYN-004, SYN-020, VCN-01, SYN-006, SYN-007, SYN-005, and VCN-11. This is the company’s core R&D base, and each asset targets a different unmet medical need, so pipeline breadth is its main value driver.
For a development-stage biotech, the real test is clinical progress and cash runway, not just asset count.
Engineered biologics platform
Theriva Biologics, Inc.'s key resource is its engineered recombinant biologics platform, the core know-how behind its pipeline. It supports gut, infectious, and oncology programs, and in 2025 the company advanced multiple candidates from the same technical base, making the platform the main source of repeatable R&D leverage.
Clinical agreements and study network
Theriva Biologics relies on active collaboration and trial agreements with academic and medical centers to secure patients, investigators, and the clinical sites needed to run human studies. In 2025, the Company was advancing three clinical-stage programs, so these partnerships are a core resource, not just support.
Scientific and translational expertise
Theriva Biologics needs deep scientific and translational expertise in microbiology, gastrointestinal biology, immunology, and oncology to pick the right targets and shape clinical trials. That know-how also helps the company read biomarker and safety data correctly, which is critical when moving live biotherapeutic and oncology programs into the clinic.
Guides target selection and trial design
Supports biomarker and safety interpretation
Links microbiology, GI biology, immunology, oncology
Intellectual property and regulatory data
Theriva Biologics’ key resources are its proprietary IP and clinical data from assets like VCN-01, including Phase 2 readouts. In biotech, this package protects differentiation, strengthens partner talks, and can support future licensing or commercialization.
- Proprietary IP shields the platform.
- Clinical data de-risks partnering.
- Phase 2 results can unlock licensing value.
Theriva’s 2025 Edge: 7 Assets, 3 Programs, and VCN-01
Theriva Biologics’ key resources are its 7 pipeline assets and its recombinant biologics platform, which support 3 clinical-stage programs in 2025. Its main value also comes from trial-site partnerships, deep translational know-how, and proprietary IP around assets like VCN-01.
| Key resource | 2025 data |
|---|---|
| Pipeline assets | 7 |
| Clinical-stage programs | 3 |
| Lead data base | Phase 2 VCN-01 |
Value Propositions
Microbiome protection during antibiotics
SYN-004 is built to break down commonly used intravenous beta-lactam antibiotics in the GI tract, so less drug reaches the gut and the microbiome is less disrupted. That matters because antibiotic-associated diarrhea affects up to 30% of patients, and preserving gut flora can cut collateral damage from therapy.
Lower CDI and AMR risk
Theriva Biologics targets Clostridioides difficile infection and antimicrobial resistance, aiming to cut gut antibiotic exposure so pathogen overgrowth and resistance pressure drop. That matters in hospitalized patients, where CDI and AMR drive longer stays, higher readmission risk, and costly care.
aGVHD prevention support
SYN-004 and SYN-006 are being developed for allogeneic hematopoietic cell transplant settings to help lower acute graft-versus-host disease risk. aGVHD affects about 30% to 50% of transplant recipients, and severe cases can carry mortality above 50%, so prevention targets a high-morbidity gap in care.
Oral intestinal alkaline phosphatase therapy
Theriva Biologics' SYN-020 is an oral recombinant intestinal alkaline phosphatase built for local gut effects and broader systemic use. As a novel oral biologic, it targets inflammatory and barrier-driven diseases with a simpler dosing path than injected proteins, and its value sits in a wide, first-in-class style therapeutic reach.
- Oral biologic, not an injection
- Local GI plus systemic potential
- Broad disease applicability
- Novel mechanism, high differentiation
Oncolytic cancer treatment candidates
Theriva Biologics, Inc. is positioning VCN-01 and VCN-11 for hard-to-treat tumors with high unmet need, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Pancreatic cancer alone had about 510,000 new cases and 467,000 deaths globally in 2022, underscoring the value of a differentiated oncolytic biologic approach in oncology.
- VCN-01 and VCN-11 target resistant solid tumors
- Focus areas include pancreatic and colorectal cancer
- Addresses high unmet need with biologic differentiation
Theriva Targets GI Protection and Precision Oncology
Theriva Biologics' value proposition is a pipeline built around local GI protection and targeted biologic action, from oral microbiome-sparing therapies to tumor-selective oncology programs. The core pitch is simple: reduce collateral damage, address high-unmet-need diseases, and use differentiated delivery or mechanisms to stand out in crowded markets.
| Theme | Value |
|---|---|
| GI support | Less gut antibiotic exposure |
| Oncology | High-unmet-need tumors |
Customer Relationships
Academic co-development
Theriva Biologics’ academic co-development model supports its 2025 clinical work, including Phase 2 trial design, by pairing the company with university and hospital experts. These collaborations help validate the science and give Theriva access to specialized disease insight in hard-to-treat cancers.
Clinical investigator engagement
Theriva Biologics, Inc. relies on a high-touch physician network to run studies and enroll patients, so trust, clean protocol design, and data quality matter more than scale. In its latest filing, the company remained a development-stage biotech with no product revenue, which makes investigator engagement a core execution lever, not a support function.
Trial-site support
Theriva Biologics must keep hospitals and trial sites in close contact, with hands-on help for enrollment, monitoring, and data capture. In small clinical programs, even one delayed site can slow readouts, so stronger site support improves execution speed and consistency.
Partner-management relationships
Theriva Biologics’ partner-management relationships are built on long-term, development-led coordination with external scientific partners, with regular project updates, milestone checks, and data sharing. In a 3-month rhythm, this keeps trial work aligned and helps avoid delays in 12+ month development cycles.
- Regular scientific and business check-ins
- Milestone tracking and shared data
- Long-term, development-focused ties
This setup matters most in clinical-stage biotech, where each update can affect study timing, budgets, and next-step decisions.
Regulatory-facing communication
Theriva Biologics’ customer relationships are tightly regulated, because clinical programs need disciplined updates on protocol, safety, and evidence generation. In 2025, that meant steady regulator-facing reporting around its lead clinical program, VCN-01, to support credibility and keep development moving.
- Protocol compliance matters for trial continuity
- Safety reports support regulator trust
- Evidence updates reduce development friction
- One lead program keeps oversight focused
Theriva’s 2025 ties were all about high-touch trial execution
Theriva Biologics’ customer relationships in 2025 stayed centered on investigators, hospitals, and academic partners, with frequent check-ins, shared data, and tight protocol control to keep small trials moving. With no product revenue and a development-stage model, each site relationship directly affected VCN-01 study speed, data quality, and readout risk.
| 2025 signal | Why it matters |
|---|---|
| No product revenue | High-touch trial ties |
| Lead program: VCN-01 | Focused oversight |
Channels
Hospital and academic trial sites
Theriva Biologics, Inc. uses specialist hospitals and university centers as its main clinical trial channel, because these sites give access to eligible patients and the staff needed to run regulated studies. They also generate the clinical data that supports endpoints, safety readouts, and regulatory filings across oncology and other programs.
Partner institutions
Academic and medical collaborators are Theriva Biologics, Inc.’s direct path from lab work to human studies, especially for early oncology and microbiome programs. As a development-stage company with no product revenue in its latest filed annual results, it depends on these partners to move candidates into clinical trials and extend scientific reach.
Scientific publications and meetings
Scientific publications and meetings let Theriva Biologics, Inc. share VCN-01 and other pipeline data with physicians, researchers, and partners before broad commercial launch. For an early-stage biotech with limited revenue visibility, that third-party validation matters more than ads; major medical congresses often draw 20,000+ attendees, giving each presentation outsized reach.
Clinical trial registries
Clinical trial registries make Theriva Biologics, Inc. studies easy to find for investigators and patients, and each listing also tells the market where the program stands: preclinical, Phase 1, 2, or 3. ClinicalTrials.gov is the main public channel, so a registered study keeps the asset visible and credible.
- Boosts study discoverability
- Signals development stage
- Supports biotech market transparency
Direct partnering outreach
Theriva Biologics, Inc. uses direct partnering outreach to contact pharma, biotech, and research institutions for licensing, co-development, and funding talks. This is a core channel for a company with no marketed products and no product revenue, so partner deals are key to pipeline progress and non-dilutive capital.
- Targets pharma, biotech, research groups
- Supports licensing and co-development
- Drives strategic funding talks
- Critical without marketed products
Theriva’s Growth Runs Through Trials, Partners, and Deal Making
Theriva Biologics, Inc. channels are mostly clinical and partner-led: hospital and university trial sites, academic collaborators, ClinicalTrials.gov, and direct outreach to pharma and biotech. In its 2025 Form 10-K, Theriva Biologics, Inc. reported no product revenue, so these channels are the main route to data, visibility, and deal talks.
| Channel | Role |
|---|---|
| Trial sites | Enroll patients |
| Academic partners | Advance studies |
| ClinicalTrials.gov | Public visibility |
| Partner outreach | Licensing talks |
Customer Segments
Allogeneic transplant centers
Allogeneic transplant centers are the core users for Theriva Biologics, Inc. SYN-004 and SYN-006 concepts, because they treat patients facing a 30% to 50% acute graft-versus-host disease risk and high infection pressure after transplant. These centers need therapies that fit ICU-level monitoring, drug–drug interaction control, and fast recovery pathways in a setting where 2025 allogeneic transplant volumes remain high across major referral hubs.
Antibiotic-treated hospitalized patients
Theriva Biologics, Inc. targets hospitalized patients on intravenous or oral beta-lactam antibiotics, a group with high microbiome injury and elevated risk of antibiotic-associated diarrhea and Clostridioides difficile infection. In U.S. hospitals, beta-lactams are among the most used antibiotic classes, and antibiotic exposure can raise CDI risk by about 2 to 3 times, making GI-protection assets a direct fit for this segment.
Oncology treatment centers
Oncology treatment centers are a core customer segment for Theriva Biologics, especially sites treating pancreatic, head and neck, colorectal, and rare pediatric tumors. These centers need new biologics for hard-to-treat cancers, and they are key sites for VCN-01 and VCN-11 studies, where one successful late-stage oncology trial can reach hundreds of patients across major cancer networks.
Pediatric infectious-disease markets
SYN-005 targets pertussis prevention and treatment, so Theriva Biologics, Inc. serves pediatric patients and infectious-disease care teams. CDC reported 35,435 U.S. pertussis cases in 2024, the highest since 2012, which shows the need for vaccines that also manage breakthrough infections and protect infants.
- Pediatric demand is outbreak-linked
- Primary use: pertussis prevention
- Also fits breakthrough-treatment need
Biopharma and research partners
Biopharma and research partners are a key customer segment for Theriva Biologics, Inc. because they can license assets, fund studies, or co-develop programs. In Theriva Biologics, Inc.’s latest public filings, partnership-led work remains the main path to commercialization, with 2025 revenue still at $0 and research spend above $10 million, so external collaborators matter more than direct sales.
License assets and shared IP
Fund trials and preclinical work
Co-develop programs for market access
Theriva’s High-Stakes Bet on Partnered Biotech Growth
Theriva Biologics, Inc. serves transplant centers, oncology hospitals, pediatric infectious-disease teams, and biopharma partners, with demand tied to severe infection, cancer, and microbiome-risk care paths. Its 2025 model still leans on partnered development, as revenue stayed at $0 while research spend remained above $10 million.
| Segment | Need | 2025 signal |
|---|---|---|
| Transplant centers | GVHD, infection control | 30% to 50% risk |
| Oncology centers | Hard-to-treat tumors | Late-stage trial sites |
| Partners | Funding, licensing | $0 revenue |
Cost Structure
Clinical trial spending
Theriva Biologics, Inc.’s clinical trial spending is the main cost driver in its early-stage model, with human studies absorbing site fees, patient monitoring, data management, and safety reporting. In 2025, clinical-stage biotech firms typically put most R&D cash into trials, often 60%+ of spending, so each new study can quickly raise burn and funding needs.
R&D laboratory costs
In fiscal 2025, Theriva Biologics kept R&D as a core cash use, because discovery, translational, and preclinical work all need ongoing assay, biomarker, and model-system spend. Each added pipeline asset raises lab load and pushes costs up, so the cost base stays tied to how many programs move in parallel.
Manufacturing and CMC costs
Theriva Biologics, Inc. must fund process development, GMP manufacturing, analytical testing, and batch release before any biologic can move into later-stage studies. These CMC steps are a fixed near-term cash drain for small biotech firms, and they often scale with each new lot and release cycle.
Regulatory and quality costs
Theriva Biologics, Inc. must keep paying for IND support, regulatory submissions, and quality systems because biotech trials cannot run without them; clinical development also needs ongoing compliance monitoring. These are recurring, non-optional costs, and for a cash-limited biotech they usually sit inside R&D and G&A burn, so even one delayed filing or audit can push spending higher.
- IND filings need steady support
- Quality systems are always on
- Compliance monitoring runs through trials
- Regulatory work is not optional
General and administrative costs
Theriva Biologics, Inc. general and administrative costs cover payroll, legal, finance, and IP work, plus the extra load of public-company reporting. As a clinical-stage firm with no product sales, G&A supports the business but does not create revenue; in its latest filing, this cost base remained a key cash use.
- Payroll, legal, finance, IP
- SEC reporting adds cost
- Supports ops, not sales
Theriva’s 2025 Burn Was Driven by R&D, Not Revenue
Theriva Biologics, Inc.’s cost structure in fiscal 2025 was dominated by R&D, led by clinical trial spend, CMC work, preclinical labs, and regulatory compliance. As a clinical-stage company with no product sales, G&A stayed a steady cash use for payroll, legal, finance, and SEC reporting.
| Cost item | 2025 role |
|---|---|
| Clinical trials | Main burn driver |
| CMC and testing | Per-lot cash drain |
| G&A | Public-company overhead |
Revenue Streams
Collaboration revenue
Theriva Biologics, Inc. can generate collaboration revenue from research and development deals with academic or industry partners, where costs and project support are shared before any product launch. As a clinical-stage biotech with no marketed products, this is a standard precommercial revenue line in 2025, and it can help offset R&D spend.
Upfront license fees
Upfront license fees can give Theriva Biologics, Inc. cash before a product is approved, especially when a program has clear outside interest and strong data. For a company still investing in pipeline work, this turns R&D value into near-term funding and can reduce dilution pressure versus raising more equity.
Milestone payments
Theriva Biologics, Inc. can earn milestone payments when a partner hits clinical or regulatory steps, so cash comes in as programs advance, not just at signing. This matters for a multi-asset pipeline because milestone-linked revenue helps fund trials while reducing pressure on dilution; in its latest filings, Theriva had no product sales and depended on external financing and collaboration-related income.
Future product sales
Theriva Biologics, Inc. has no approved products yet, so revenue from future product sales is still zero today. If one of its GI, infectious-disease, or oncology candidates wins approval, direct sales could become a major revenue stream; until then, the company remains clinical-stage and depends on capital to fund trials.
- No product sales yet
- Clinical-stage company
- Sales depend on approval
- Targets GI, infection, oncology
Grants and non-dilutive funding
Grants and public funding can add non-dilutive cash, helping Theriva Biologics, Inc. fund early-stage science without issuing new shares. This support often comes from research programs or government sources, so it can extend runway while keeping equity dilution lower.
- Reduces dilution risk
- Funds early R&D
- Supports operating cash
Theriva’s 2025 Revenue: All Precommercial, No Product Sales
Theriva Biologics, Inc. had no product sales in 2025, so revenue still depends on collaboration deals, upfront license fees, milestone payments, and grants. That means cash inflow is mostly tied to partner activity and research funding, not commercial demand.
| Stream | 2025 status |
|---|---|
| Product sales | Zero |
| Collab. and license income | Precommercial cash |
| Milestones and grants | Non-dilutive support |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.